Venture Capital: J.P. Morgan Launches Life Sciences V.C. Team As Part Of Private Capital Platform

November 2, 2022 | News, Venture Capital

Life Sciences Private Capital will invest in early and growth stage healthcare companies.

J.P. Morgan Asset Management today announced the launch of a new life sciences private equity team, Life Sciences Private Capital, as part of its J.P. Morgan Private Capital arm, a growth equity and private credit investment platform.

The new Life Sciences team will invest in both early and growth stage healthcare companies across multiple strategies aligned to specific market opportunities, with a focus on novel therapeutics and technologies in several target areas including Genetic Medicine, Oncology, Neurodegenerative Disease, Rare Diseases, Autoimmunity, AI/ML platforms, Metabolic Diseases and Neuropsychology. (CISION PR Newswire)

J.P. Morgan: Life Sciences Private Capital

Industry expert Dr. Stephen Squinto has been appointed as Chief Investment Officer and Managing Partner of Life Sciences Private Capital.

Dr. Squinto joins from OrbiMed Advisors and brings more than 30 years of experience in the biotechnology company building and investing space, having co-founded and built numerous biotechnology companies including Alexion Pharmaceuticals and acting as a key scientific founder of Regeneron Pharmaceuticals.

“As advances in genomics, biomarkers and data science converge, we are seeing firsthand the transformative impact that biomedical innovation can offer to patients at all stages of life and we expect much more to come in the next decade,” said Dr Squinto. “J.P. Morgan’s existing presence in the healthcare sector will give us a significant sourcing advantage as we seek to identify innovative and transformative therapeutics companies.”

“Our new Life Sciences Private Capital team combines some of the industry’s most revered biotech investors, operators and founders with J.P. Morgan’s extensive healthcare ecosystem to capture compelling investment opportunities in the biotech sector, which is on the cusp of a golden age of therapeutic innovation,” said Brian Carlin, Chief Executive Officer, J.P. Morgan Private Capital.

Related Story: AI-Powered, Precision Medicine Startup Tempus Raises $275M In Equity And Debt

Photo by Lucas Vasques on Unsplash

Free Industry News

Subscribe to our free newsletter for updates and news about alternatives investments.

  • This field is for validation purposes and should be left unchanged.


Latest Alternative Investment News
Alternative Investments/ESG: Six New Responsible Funds Flag Off Morgan Stanley’s ETF Platform

Morgan Stanley Investment Management (MSIM) has launched its ETF platform with six Calvert ETFs listed on NYSE Arca. The ETFs feature Calvert’s responsible investing approach and offer access to four…
Artificial Intelligence: MusicLM, A New Generative AI Tool From Google, Creates Music From Text
February 2, 2023     Artificial Intelligence, News

Google (NASDAQ: GOOGL) recently published a research paper on its new AI tool, MusicLM, designed to create music. The tool is based on machine learning and is trained on vast…
Artificial Intelligence: Snap Mulling AR Glasses Powered By Generative AI
February 2, 2023     Artificial Intelligence, News

Snap (NYSE: SNAP), the parent company of Snapchat, has hinted at future AR glasses powered by generative AI technology. CEO Evan Spiegel stated that AI will be critical to the…
Digital Assets: Binance And Mastercard Launch Prepaid Crypto Card In Brazil
February 1, 2023     Digital Assets, News

Binance and Mastercard (NYSE: MA) have jointly launched the Binance Card in Brazil, allowing Binance users in the country to make purchases and pay bills with cryptocurrencies like bitcoin and…